Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Access the full publication here: JAMA Publishes ACHIEVE-5 Trial Results on GLP-1 Receptor Agonist Now Published in JAMA: ACHIEVE-5 Trial Results An Oral GLP-1 Receptor Agonist Added to Titrated Basal Insulin in Type 2 Diabetes
Tirzepatide is a newer medication that activates both GLP-1 and GIP receptors, another gut hormone
Lowers risk of heart failure and stroke The protective effects of GLP-1 medications translate into impressive reductions in serious cardiovascular events
In diabetes management, it not only helps to lower fasting blood sugar and postprandial blood sugar, but also improves insulin sensitivity and reduces the risk of diabetic complications
Enable cumulative counters in eMAR and duplicate-therapy alerts
:max_bytes(150000):strip_icc()/Health-GettyImages-1675158771-70640c9fdf1b41078975cfc3fd538a6b.jpg)
US$ 25.39
US$ 22.52
US$ 20.78
US$ 20.75
US$ 21.45
